Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort's new form of physiological treatment with once-a-day hydrocortisone dosing show improved cardiovascular and metabolic measures compared to standard hydrocortisone tablets given thrice daily. The company presents the data at the 91st annual ENDO congress in Washington DC.

Today in Other Drugs...keeping you current

Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
Medicinal Research Reviews, 12/09/09

Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol
Therapeutics and Clinical Risk Management, 12/09/09

Pharmacotherapy of diabetic foot osteomyelitis
Expert Opinion in Pharmacotherapy, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address